Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indinavir Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.99 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.99 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.99 |
| ▸ | TACR2 | P21452 | 1/20 | 0.99 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.99 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.99 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.99 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indinavir Anhydrous SCHEMBL17787450 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL7752012 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL8033526 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL6766271 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL2671734 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL14287519 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL20399698 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL21683359 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL21578565 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL1176257 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | CYP3A4 4785/4885ABCC3 834/4885ABCB11 187/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | CYP3A4 4785/4885ABCC3 834/4885ABCB11 187/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | CYP3A4 2045/4885ABCC3 1436/4885ABCB11 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.